Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide

BACKGROUND: While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Sugimoto, Yuka, Sekeres, Mikkael A, Makishima, Hideki, Traina, Fabiola, Visconte, Valeria, Jankowska, Anna, Jerez, Andres, Szpurka, Hadrian, O'Keefe, Christine L, Guinta, Kathryn, Afable, Manuel, Tiu, Ramon, McGraw, Kathy L, List, Alan F, Maciejewski, Jaroslaw
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2012
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3323440/
https://ncbi.nlm.nih.gov/pubmed/22390313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-5-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi